Flubromazolam
Standing risks
| Risk | Recorded values | Confidence | Article section |
|---|---|---|---|
| Dangerous withdrawal, taper carefully |
| low | View in article: Dangerous withdrawal, taper carefully |
| High overdose risk, use caution |
| medium | View in article: High overdose risk, use caution |
| Compulsive use risk, monitor frequency |
| medium | View in article: Compulsive use risk, monitor frequency |
| High dependence, taper carefully |
| medium | View in article: High dependence, taper carefully |
| Chronic toxicity, limit exposure |
| medium | View in article: Chronic toxicity, limit exposure |
Lethal interactions
| Combination | Type | Severity | Mechanisms | Confidence |
|---|---|---|---|---|
| Opioids | Drug class | lethal | 2 | high |
Dangerous interactions
21 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
| Condition | Severity | Note |
|---|---|---|
| Respiratory | ||
| opioid co-use | absolute | Co-administration with any opioid is an absolute contraindication. FDA black box warning applies to all opioid-benzodiazepine combinations. 92.7% of illicit benzodiazepine-involved deaths involve opioids. Flubromazolam has been documented as an adulterant in unregulated opioid supplies. |
| alcohol co-use | absolute | Co-administration with alcohol is an absolute contraindication. Synergistic CNS depression documented in polydrug fatality case series. |
| other CNS depressant co-use | absolute | other benzodiazepines, Z-drugs, gabapentinoids, barbiturates, muscle relaxants, sedating antipsychotics, tricyclic antidepressants, sedating antihistamines Co-administration with other CNS depressants carries absolute contraindication status. In English/Welsh coronial data, flubromazolam co-occurred with other designer benzodiazepines in 48% of cases. |
| Neurological | ||
| epilepsy | relative | Relative contraindication. Benzodiazepines are acutely anticonvulsant but flubromazolam's dependence risk and withdrawal seizure potential are hazardous for epilepsy patients. |
| Pregnancy & Breastfeeding | ||
| pregnancy and breastfeeding | absolute | No published data exist for flubromazolam in pregnancy or breastfeeding. Class-level concerns include neonatal withdrawal syndrome. Absolute contraindication by precautionary principle. |
| Other | ||
| CYP3A4 inhibitor co-administration | relative | itraconazole, ketoconazole, voriconazole, ritonavir, clarithromycin, grapefruit juice Potent CYP3A4 inhibitors are a relative contraindication. Mechanistic prediction from in vitro metabolism data is strong but no controlled interaction studies exist. |
| benzodiazepine hypersensitivity | absolute | Known hypersensitivity to any benzodiazepine is an absolute contraindication. |